Serum Neurofilament Levels and PML Risk in Patients With Multiple Sclerosis Treated With Natalizumab.
Nicolás FissoloBeatrice PignoletJordi RioPatrick VermerschAurélie RuetJerome deSèzePierre LabaugeSandra VukusicCaroline PapeixLaurent Martinez-AlmoynaAyman TourbahPierre ClavelouThibault MoreauJean PelletierChristine Lebrun-FrénayBertrand BourreGilles DeferXavier MontalbanDavid BrassatManuel Comabella LopezPublished in: Neurology(R) neuroimmunology & neuroinflammation (2021)
This study provides Class I evidence that serum NFL levels can identify NTZ-treated patients with MS who will develop PML with a sensitivity of 67% and specificity of 80%.